Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Industry Update
15 September 2023

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13

Authors: Benjamin D Bray and Sreeram V Ramagopalan [email protected]Author Info & Affiliations
Volume 12, Number 11
https://doi.org/10.57264/cer-2023-0141
PDFFormats

Abstract

In this latest update we highlight a report from the European Medicines Agency on their use of real-world evidence (RWE) in decision making, RWE reporting guidance from the Canadian Agency for Drugs and Technologies in Health and highlight some new data demonstrating the value medicines for spinal muscular atrophy have brought patients.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
European Medicines Agency. Use of real-world evidence in regulatory decision making – EMA publishes review its studies. https://www.ema.europa.eu/en/news/use-real-world-evidence-regulatory-decision-making-ema-publishes-review-its-studies (2023).
Google Scholar
2.
McDonald L, Schultze A, Carroll R, Ramagopalan SV. Performing studies using the UK Clinical Practice Research Datalink: to link or not to link? Eur. J. Epidemiol. 33, 601–605 (2018).
PubMed
Google Scholar
3.
McDonald L, Ramagopalan SV, Lees M. Real-world data really matter. CMAJ. 189, E1293 (2017).
PubMed
Google Scholar
4.
McDonald L, Schultze A, Simpson A, Graham S, Wasiak R, Ramagopalan SV. Lack of data sharing in observational studies. BMJ. 359, j4866 (2017).
PubMed
Google Scholar
5.
6.
Cox O, Sammon C, Simpson A, Wasiak R, Ramagopalan S, Thorlund K. The (harsh) reality of real-world data external comparators for health technology assessment. Value Health. 25, 1253–1256 (2022).
Crossref
PubMed
Google Scholar
7.
CADTH. Guidance for Reporting Real-World Evidence. https://www.cadth.ca/guidance-reporting-real-world-evidence
Google Scholar
8.
Wang SV, Pottegård A, Crown W et al. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR task force. Pharmacoepidemiol. Drug Saf. 32, 44–55 (2023).
PubMed
Google Scholar
9.
Bray B, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11. J. Comp. Eff. Res. 12(5), e230008 (2023).
PubMed
Google Scholar
10.
Leahy TP, Kent S, Sammon C et al. Unmeasured confounding in nonrandomized studies: quantitative bias analysis in health technology assessment. J. Comp. Eff. Res. 11(12), 851–859 (2022).
PubMed
Google Scholar
11.
Bray B, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12. J. Comp. Eff. Res. 12(7), e230092 (2023).
PubMed
Google Scholar
12.
Ramagopalan SV, Treharne C, Pearson-Stuttard J, Subbiah V. For what it's worth: the complex area of medicine value assessment. J. Comp. Eff. Res. 12(9), e230120 (2023).
PubMed
Google Scholar
|